医学
肾癌
全身疗法
肾细胞癌
癌症
内科学
阶段(地层学)
肿瘤科
肾脏疾病
重症监护医学
生物
古生物学
乳腺癌
作者
Robert J. Motzer,Eric Jonasch,Neeraj Agarwal,Ajjai Alva,Michael J. Baine,Kathryn E. Beckermann,Maria I. Carlo,Toni K. Choueiri,Brian A. Costello,Ithaar Derweesh,Arpita Desai,Yasser Ged,Saby George,John L. Gore,Naomi B. Haas,Steven Hancock,Payal Kapur,Christos E. Kyriakopoulos,Elaine T. Lam,Primo N. Lara
出处
期刊:Journal of The National Comprehensive Cancer Network
日期:2022-01-01
卷期号:20 (1): 71-90
被引量:449
标识
DOI:10.6004/jnccn.2022.0001
摘要
The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor histology and risk stratification of patients is important in therapy selection. The NCCN Guidelines for Kidney Cancer stratify treatment recommendations by histology; recommendations for first-line treatment of ccRCC are also stratified by risk group. To further guide management of advanced RCC, the NCCN Kidney Cancer Panel has categorized all systemic kidney cancer therapy regimens as “Preferred,” “Other Recommended Regimens,” or “Useful in Certain Circumstances.” This categorization provides guidance on treatment selection by considering the efficacy, safety, evidence, and other factors that play a role in treatment selection. These factors include pre-existing comorbidities, nature of the disease, and in some cases consideration of access to agents. This article summarizes surgical and systemic therapy recommendations for patients with relapsed or stage IV RCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI